Agenus Inc. (BX:AGEN) Financings

Agenus Inc.

Financings

RaiseDate
Private placement of common stock or pre-funded warrants with Series A and Series B purchase warrants
Announced: US$85M–US$340M · an accompanying Series A purchase warrant and Series B purchase warrant that, if fully…
Buyers: Commodore Capital; RA Capital Management; TCGX; Invus; Ligand Pharmaceuticals
Use of proceeds: Advance BOT+BAL in neoadjuvant MSS colon cancer, including the registrational Phase 3 ROBBIN trial
Jul 13, 2026
Strategic investment of common stock
Closed: US$16M raised · US$7.5 a share · Porrima Ltd +1
Dealers: Porrima Ltd, Biotech Value Advisors (BVA)
Buyers: Zydus ($16 million of Agenus common stock (~2.1 million shares at $7.50 per share))
Jan 15, 2026
Strategic investment of common stock
Announced: about US$16M · US$7.5 a share
Buyers: Zydus (approximately 2.1 million shares of common stock at $7.50 per share, approximately $16 million)
Use of proceeds: Working capital and general corporate purposes, and to accelerate clinical development, registration and potential commercialization of BOT/BAL
Jun 3, 2025

Read by 6ix AI from the company's releases